Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05379985 · ClinicalTrials.gov registry record · Phase 1
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
A Phase 1 study of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC), sponsored by Revolution Medicines.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 754
- Enrollment target
- 16
- Study locations
NCT05379985: Recruiting Phase 1 study of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC), sponsored by Revolution Medicines.
NCT05379985 is a Phase 1 study of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC) that is actively recruiting participants, run by Revolution Medicines. The registered enrollment target is 754 participants, above the 193-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (291% higher). The trial reports 16 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05379985, a Phase 1 study of Advanced Solid Tumors and Non-small Cell Lung Cancer (NSCLC), is actively recruiting participants, sponsored by Revolution Medicines.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 754 participants
- Enrollment target
- 16
- Study locations
Study Summary
Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
Conditions Studied
Interventions
- DRUG RMC-6236
Study Locations (16)
Texas
- University of Texas at Austin - Austin
- Mary Crowley Cancer Research - Dallas
- The University of Texas MD Anderson Cancer Center - Houston
- Next Oncology - San Antonio
New York
- Perlmutter Cancer Center at NYU Langone Health - New York
- Memorial Sloan-Kettering Cancer Center - New York
- Columbia University - New York
California
- UC Irvine/Chao Family Comprehensive Cancer Center - Orange
- UCLA - Santa Monica
Florida
- Moffitt Cancer Center - Tampa
Maryland
- Johns Hopkins University - Baltimore
Massachusetts
- Dana Farber Cancer Institute - Boston
Ohio
- Christ Hospital Cancer Center - Cincinnati
Tennessee
- Sarah Cannon Research Institute - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 754 participants |
| Start Date | 2022-05-31 |
| Est. Completion | 2027-07-26 |
| Phase | Phase 1 |
What NCT05379985 shows while recruiting
NCT05379985 is an interventional study that assigns participants to a tested intervention. The registered 754 participants enrollment target is mid-sized for trials with a published cap, above the 193-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (291% higher).
The record links to 4 conditions, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which RMC-6236 is the first listed.
NCT05379985 lists 16 locations in 10 states (Texas, New York, California).
Frequently Asked Questions
What is clinical trial NCT05379985 about?
NCT05379985 is a clinical study titled "Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS". Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.
What is the current status of trial NCT05379985?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 754 participants. The study started on 2022-05-31. Estimated completion is 2027-07-26.
What conditions does trial NCT05379985 study?
This clinical trial studies the following conditions: Advanced Solid Tumors, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC).
What interventions are being tested in trial NCT05379985?
The interventions under investigation include: RMC-6236 (DRUG).
Who is sponsoring clinical trial NCT05379985?
This trial is sponsored by Revolution Medicines, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05379985 being conducted?
This trial has 16 study locations across California, Florida, Maryland, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05379985's enrollment target sits among peer trials
754 5th of 144 higher than 140 of 144 other Advanced Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
RECRUITING · Phase 1
-
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RECRUITING · Phase 1
-
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
RECRUITING · Phase 1
-
SNV4818 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05427370 · 754 participants · NA
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
- NCT05869149 · 756 participants · NA
Systems Science Approaches to Improve Access to Healthier Foods: The FRESH Trial
- NCT06095583 · 756 participants · Phase 3
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
- NCT06559306 · 752 participants · Phase 3
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI